CA2085224A1 - Hybrid plasminogen activators - Google Patents

Hybrid plasminogen activators

Info

Publication number
CA2085224A1
CA2085224A1 CA002085224A CA2085224A CA2085224A1 CA 2085224 A1 CA2085224 A1 CA 2085224A1 CA 002085224 A CA002085224 A CA 002085224A CA 2085224 A CA2085224 A CA 2085224A CA 2085224 A1 CA2085224 A1 CA 2085224A1
Authority
CA
Canada
Prior art keywords
compound according
hybrid
plasminogen
chain
glu1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002085224A
Other languages
English (en)
French (fr)
Inventor
Jeffery H. Robinson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beecham Group PLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2085224A1 publication Critical patent/CA2085224A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52Genes encoding for enzymes or proenzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424Serine endopeptidases (3.4.21)
    • C12N9/6435Plasmin (3.4.21.7), i.e. fibrinolysin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424Serine endopeptidases (3.4.21)
    • C12N9/6456Plasminogen activators
    • C12N9/6459Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21Serine endopeptidases (3.4.21)
    • C12Y304/21007Plasmin (3.4.21.7), i.e. fibrinolysin
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21Serine endopeptidases (3.4.21)
    • C12Y304/21069Protein C activated (3.4.21.69)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Fixing For Electrophotography (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002085224A 1990-06-14 1991-06-12 Hybrid plasminogen activators Abandoned CA2085224A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9013345.5 1990-06-14
GB909013345A GB9013345D0 (en) 1990-06-14 1990-06-14 Novel compounds

Publications (1)

Publication Number Publication Date
CA2085224A1 true CA2085224A1 (en) 1991-12-15

Family

ID=10677652

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002085224A Abandoned CA2085224A1 (en) 1990-06-14 1991-06-12 Hybrid plasminogen activators

Country Status (12)

Country Link
EP (1) EP0535037A1 (pt)
JP (1) JPH05506363A (pt)
KR (1) KR930701607A (pt)
AU (1) AU648567B2 (pt)
CA (1) CA2085224A1 (pt)
GB (1) GB9013345D0 (pt)
IE (1) IE911999A1 (pt)
IL (1) IL98478A0 (pt)
NZ (1) NZ238506A (pt)
PT (1) PT97983A (pt)
WO (1) WO1991019793A2 (pt)
ZA (1) ZA914520B (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1135475A1 (en) * 1998-12-02 2001-09-26 Oklahoma Medical Research Foundation Human plasminogen activator

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ191320A (en) * 1978-09-07 1982-09-14 Beecham Group Ltd In vivo fibrinolytic enzyme having active site blocked by hydrolytically removable group pharmaceutical compositions
GB8334498D0 (en) * 1983-12-24 1984-02-01 Beecham Group Plc Compounds
EP0297882B1 (en) * 1987-07-01 1993-08-25 Beecham Group Plc Hybrid plasminogen activators
GB9019120D0 (en) * 1990-09-01 1990-10-17 Beecham Group Plc Novel compounds

Also Published As

Publication number Publication date
IE911999A1 (en) 1991-12-18
AU8068191A (en) 1992-01-07
IL98478A0 (en) 1992-07-15
AU648567B2 (en) 1994-04-28
GB9013345D0 (en) 1990-08-08
KR930701607A (ko) 1993-06-12
ZA914520B (en) 1992-12-30
PT97983A (pt) 1992-04-30
EP0535037A1 (en) 1993-04-07
NZ238506A (en) 1993-07-27
WO1991019793A3 (en) 1992-01-23
JPH05506363A (ja) 1993-09-22
WO1991019793A2 (en) 1991-12-26

Similar Documents

Publication Publication Date Title
US4908204A (en) Reversibly blocked plasmin, t-PA hybrid fibrinolytic enzymes and pharmaceutical compositions and anti-thrombotic use thereof
US4970159A (en) Human tissue plasminogen activator consisting essentially of t-PA residues 160 to 527
US5385732A (en) Variants of tissue plasminogen activator, compositions and methods of use for same
WO1991018989A1 (en) Hybrid plasminogen activator mutants
RU2143490C1 (ru) Бифункциональный вариант урокиназы, плазмида, содержащая синтетический структурный ген, кодирующий бифункциональную урокиназу, плазмида (варианты), способ получения плазмиды, способ получения бифункционального варианта урокиназы, тромболитическое средство
EP0297882B1 (en) Hybrid plasminogen activators
US4999194A (en) Two-chain urokinase plasminogen activators for treatment of thrombotic disease
US5302390A (en) Hybrid proteins of human plasminogen and human t-PA, pharmaceutical compositions and methods of treatment
AU648567B2 (en) Hybrid plasminogen activators
CA2145749C (en) Thrombin activatable plasminogen derivatives
Robinson et al. A recombinant, chimeric enzyme with a novel mechanism of action leading to greater potency and selectivity than tissue-type plasminogen activator.
NL8700013A (nl) Hybride plasminogeenactivatoren met verbeterde trombolytische eigenschappen en geneesmiddelen die deze plasminogeenactivatoren bevatten.
WO1992004450A1 (en) Hybrid plasminogen activators
EP0250071A1 (en) Fibrinolytic enzymes, processes for their preparation and their use
US5736134A (en) Tissue plasminogen activator variants
EP0336508A1 (en) Recombinant human single-chain urokinase-type plasminogen activator mutant produced by site-specific mutagenesis of lysine 158 to histidine 158
US5234686A (en) Human tissue plasminogen activator consisting essentially of t-PA residues to 160 to 527, pharmaceutical compositions and methods of treatment
EP0292326A2 (en) Modified enzyme
AU670774B2 (en) Novel tissue plasminogen activator variants
EP0370711A1 (en) Novel compounds
KR20000029755A (ko) 트롬빈에의해활성화될수있는플라스미노겐활성화제
HU210541A9 (hu) Zimogén- vagy fibrin-specifikus tulajdonságú, a 296-299 aminosav-tartományban helyettesített szöveti plazminogén aktivátor, ezt kódoló DNS-molekulák, vektorok és gazdasejtek

Legal Events

Date Code Title Description
FZDE Discontinued